The Alzheimer's Biomarker Consortium-Down Syndrome: Rationale and methodology

Authors

Benjamin L Handen, University of Pittsburgh
Anne M Fagan, Washington University School of Medicine in St. Louis
Beau Ances, Washington University School of Medicine in St. Louis
et al

Journal

Alzheimers & Dementia: Diagnosis, Assessment & Disease Monitoring

Publication Date

1-1-2020

Volume

12

Issue

1

First Page

e12065

Document Type

Open Access Publication

DOI

10.1002/dad2.12065

Rights and Permissions

Handen, BL, Lott, IT, Christian, BT, et al. The Alzheimer's Biomarker Consortium-Down Syndrome: Rationale and methodology. Alzheimer's Dement. 2020; 12:e12065. https://doi.org/10.1002/dad2.12065 © 2020 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, Inc. on behalf of Alzheimer's Association This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Recommended Citation

Handen, Benjamin L; Fagan, Anne M; Ances, Beau; and et al, "The Alzheimer's Biomarker Consortium-Down Syndrome: Rationale and methodology." Alzheimers & Dementia: Diagnosis, Assessment & Disease Monitoring. 12, 1. e12065 (2020).
https://digitalcommons.wustl.edu/open_access_pubs/11401